biostudies-literatureUnknown2(3)Lenci E<h4>Aim</h4>The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of TB in a real-world sample of advanced NSCLC patients.<h4>Methods</h4>Sixty-five consecutive patients with advanced NSCLC treated with immunotherapy as first or second line therapy were retrospectively analyzed between August 2015 and February 2018. TB was recorded at baseline considering sites and number of metastases, thoracic <i>vs</i>. extrathoracic disease, measurable disease (MD) <i>vs</i>. not-MD (NMD) and evaluating dimensional aspects as maximum lesion diameter (cut-off = 6.3 cm), sum of the 5 major lesions diameters (cut-off = 14.3 cm), and number of sites of metastases (cut-off > 4)Exploration of targeted anti-tumor therapy227-239https://www.ebi.ac.uk/biostudies/studies/S-EPMC9400786biostudies-literatureTumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.PMC9400786Rinaldi SCognigni VMarcantognini GLupi AFiordoliva ICantini LZuccatosta LBerardi RCarloni ALRocchi MGasparini SLenci EfalseTumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.<h4>Aim</h4>The role of tumor burden (TB) for patients with non-small cell lung cancer (NSCLC) receiving immunotherapy is still unknown. The aim of this analysis was to analyze the prognostic value of TB in a real-world sample of advanced NSCLC patients.<h4>Methods</h4>Sixty-five consecutive patients with advanced NSCLC treated with immunotherapy as first or second line therapy were retrospectively analyzed between August 2015 and February 2018. TB was recorded at baseline considering sites and number of metastases, thoracic <i>vs</i>. extrathoracic disease, measurable disease (MD) <i>vs</i>. not-MD (NMD) and evaluating dimensional aspects as maximum lesion diameter (cut-off = 6.3 cm), sum of the 5 major lesions diameters (cut-off = 14.3 cm), and number of sites of metastases (cut-off > 4)2021-01-01T00:00:00Z20212025-04-22T07:03:59.34Z2025-04-05T21:58:46.732ZS-EPMC94007863604643610.37349/etat.2021.00043